Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

  1. Martin, M.
  2. Zielinski, C.
  3. Ruiz-Borrego, M.
  4. Carrasco, E.
  5. Turner, N.
  6. Ciruelos, E.M.
  7. Muñoz, M.
  8. Bermejo, B.
  9. Margeli, M.
  10. Anton, A.
  11. Kahan, Z.
  12. Csöszi, T.
  13. Casas, M.I.
  14. Murillo, L.
  15. Morales, S.
  16. Alba, E.
  17. Gal-Yam, E.
  18. Guerrero-Zotano, A.
  19. Calvo, L.
  20. de la Haba-Rodriguez, J.
  21. Ramos, M.
  22. Alvarez, I.
  23. Garcia-Palomo, A.
  24. Huang Bartlett, C.
  25. Koehler, M.
  26. Caballero, R.
  27. Corsaro, M.
  28. Huang, X.
  29. Garcia-Sáenz, J.A.
  30. Chacón, J.I.
  31. Swift, C.
  32. Thallinger, C.
  33. Gil-Gil, M.
  34. Erakutsi egile guztiak +
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2021

Alea: 32

Zenbakia: 4

Orrialdeak: 488-499

Mota: Artikulua

DOI: 10.1016/J.ANNONC.2020.12.013 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus